Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katie F Maass

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Ophthalmology|October 23, 2019
ReplyPeter A Campochiaro, Katie F Maass, Natasha Singh, et al.
The AAPS Journal|February 26, 2016
Determination of Cellular Processing Rates for a Trastuzumab-Maytansinoid Antibody-Drug Conjugate (ADC) Highlights Key Parameters for ADC DesignKatie F Maass, Chethana Kulkarni, Alison M Betts, et al.
Journal of Applied Polymer Science|September 26, 2015
Dynamic swelling behavior of interpenetrating polymer networks in response to temperature and pHBrandon V Slaughter, Aaron T Blanchard, Katie F Maass, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|March 6, 2022
In-vitro characterization of ranibizumab release from the Port Delivery SystemStefan Yohe, Katie F Maass, Judit Horvath, et al.
Nature Medicine|November 24, 2020
Will patient-centric sampling become the norm for clinical trials after COVID-19?Christopher A James, Matthew D Barfield, Katie F Maass, et al.
Journal of Pharmaceutical Sciences|September 8, 2015
A Flow Cytometric Clonogenic Assay Reveals the Single-Cell Potency of DoxorubicinKatie F Maass, Chethana Kulkarni, Mohiuddin A Quadir, et al.
Molecular Pharmaceutics|December 27, 2019
Ocular Half-Life of Intravitreal Biologics in Humans and Other Species: Meta-Analysis and Model-Based PredictionAntonello Caruso, Matthias Füth, Ruben Alvarez-Sánchez, et al.
Ophthalmology. Retina|October 24, 2024
Retinal Fluid and Thickness Fluctuations in Archway Trial for Port Delivery System with Ranibizumab versus Monthly Ranibizumab InjectionsVeeral S Sheth, Nancy M Holekamp, Arshad M Khanani, et al.
The AAPS Journal|April 1, 2016
Evolution of Antibody-Drug Conjugate Tumor Disposition Model to Predict Preclinical Tumor Pharmacokinetics of Trastuzumab-Emtansine (T-DM1)Aman P Singh, Katie F Maass, Alison M Betts, et al.
Ophthalmology and Therapy|June 27, 2022
Pharmacokinetics of the Port Delivery System with Ranibizumab in the Ladder Phase 2 Trial for Neovascular Age-Related Macular DegenerationCharles C Wykoff, Peter A Campochiaro, Dante J Pieramici, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Ophthalmology|October 23, 2019
ReplyPeter A Campochiaro, Katie F Maass, Natasha Singh, et al.
The AAPS Journal|February 26, 2016
Determination of Cellular Processing Rates for a Trastuzumab-Maytansinoid Antibody-Drug Conjugate (ADC) Highlights Key Parameters for ADC DesignKatie F Maass, Chethana Kulkarni, Alison M Betts, et al.
Journal of Applied Polymer Science|September 26, 2015
Dynamic swelling behavior of interpenetrating polymer networks in response to temperature and pHBrandon V Slaughter, Aaron T Blanchard, Katie F Maass, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|March 6, 2022
In-vitro characterization of ranibizumab release from the Port Delivery SystemStefan Yohe, Katie F Maass, Judit Horvath, et al.
Nature Medicine|November 24, 2020
Will patient-centric sampling become the norm for clinical trials after COVID-19?Christopher A James, Matthew D Barfield, Katie F Maass, et al.
Journal of Pharmaceutical Sciences|September 8, 2015
A Flow Cytometric Clonogenic Assay Reveals the Single-Cell Potency of DoxorubicinKatie F Maass, Chethana Kulkarni, Mohiuddin A Quadir, et al.
Molecular Pharmaceutics|December 27, 2019
Ocular Half-Life of Intravitreal Biologics in Humans and Other Species: Meta-Analysis and Model-Based PredictionAntonello Caruso, Matthias Füth, Ruben Alvarez-Sánchez, et al.
Ophthalmology. Retina|October 24, 2024
Retinal Fluid and Thickness Fluctuations in Archway Trial for Port Delivery System with Ranibizumab versus Monthly Ranibizumab InjectionsVeeral S Sheth, Nancy M Holekamp, Arshad M Khanani, et al.
The AAPS Journal|April 1, 2016
Evolution of Antibody-Drug Conjugate Tumor Disposition Model to Predict Preclinical Tumor Pharmacokinetics of Trastuzumab-Emtansine (T-DM1)Aman P Singh, Katie F Maass, Alison M Betts, et al.
Ophthalmology and Therapy|June 27, 2022
Pharmacokinetics of the Port Delivery System with Ranibizumab in the Ladder Phase 2 Trial for Neovascular Age-Related Macular DegenerationCharles C Wykoff, Peter A Campochiaro, Dante J Pieramici, et al.
Pageof 2